o2h ventures makes an investment
- On November 12, 2020
- By GrowthInvest Marketing
Cambridge, October 2020:
The o2h human health EIS Fund, is pleased to lead an investment into digital therapeutic Cortirio Limited alongside University of Surrey and KQ Labs. Traumatic brain injury is the leading cause of death and disability among the under 45s and a growing problem for our aging population as falls become more prevalent. Cortirio’s portable scanners can be used at the point of care to enable the early treatment of traumatic brain injuries. By saving time, this technology will save brain function and avert disability and death
Sunil Shah, CEO at o2h Ventures said: “We are very excited to invest into Cortirio’s portable brain scanner. When fully developed this could be supportive to the NHS and to other health systems around the world”.
GET IN TOUCH!
MAIL US
enquiries@growthinvest.comCALL US
020 7071 3945FOLLOW US ON
Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.
GrowthInvest is a trading name of EIS Platforms Limited. EIS Platforms Limited (FRN: 694945) is an appointed representative of Sapphire Capital Partners LLP (FRN:565716) which is authorised and regulated by the Financial Conduct Authority in the UK.
All rights reserved 2024 @ growthinvest